Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Patients With Head and Neck Cancer

医学 彭布罗利珠单抗 不利影响 头颈部癌 免疫疗法 内科学 队列 肿瘤科 共病 队列研究 癌症 放射治疗 癌症免疫疗法 重症监护医学 头颈部 口服免疫疗法 梅德林 头颈部鳞状细胞癌 中止 回顾性队列研究 相对风险 肺癌 无容量
作者
Andrew M. Peterson,Dustin L. Stwalley,Dorina Kallogjeri,Thomas F. Barrett,Alex Harbison,Patrik J. Pipkorn,Ryan S. Jackson,Sidharth V. Puram,Jay F. Piccirillo,Paul Zolkind
出处
期刊:JAMA otolaryngology-- head & neck surgery [American Medical Association]
卷期号:152 (4): 384-384
标识
DOI:10.1001/jamaoto.2025.5513
摘要

Importance: Immunotherapy is approved for first-line treatment of recurrent/metastatic head and neck cancer (HNC). The prescribing patterns are largely unreported, and assessment of immune-related adverse events (irAEs) in patients with HNC is limited. Objective: To assess the prescribing patterns of immunotherapy and the incidence and risk factors for irAEs using a claims-based database. Design, Setting, and Participants: A retrospective cohort study of MarketScan Commercial and multistate Medicaid databases of all patients with HNC from January 1, 2016, to December 31, 2022, was performed. Inclusion criteria were patients with HNC, defined by International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes with 6 months or longer of insurance enrollment prior to diagnosis and 1 or more months of follow-up. The databases excluded patients 65 years or older. Statistical analysis was conducted from October 1, 2024, through December 31, 2024. Exposure: Prescription of an immunotherapeutic within 12 months after HNC diagnosis. Outcomes: The primary outcome measure was prescribing rate of immunotherapeutics overall and per year. The relative use of each immunotherapeutic was also explored. Secondary outcome measures were incidence of irAEs, severe irAEs, and univariable/multivariate risk factors for irAEs. Results: A total of 47 365 patients with HNC were included, and 2254 (4.8%) of these patients received immunotherapy. Overall, 32 195 participants were male individuals (68%) and 14 607 were female individuals (32%), with a mean (SD) age of 54 (9) years. The rate of immunotherapy prescriptions slightly increased over time from 2.3% of patients with HNC in 2017 to 2.8% in 2022 (percent change, 0.5%; 95% CI, 0.1%-0.9%). Following initial approval by the US Food and Drug Administration (FDA), prescribing patterns of pembrolizumab and nivolumab were similar, but divergence in 2019 led to 87% of the market share dominated by pembrolizumab by 2022. The 90-day overall irAE-rate was 41.2% and severe irAE rate was 2.7%. There was no association between medication use and irAEs. Comorbidity score was associated with severe irAEs at 90 days (odds ratio [OR], 1.02; 95% CI, 1.02-1.03). Baseline hypothyroidism (adjusted OR [aOR], 6.7; 95% CI, 5.0-9.0) and liver disease (aOR, 1.7; 95% CI, 1.1-2.7) were independently associated with the development of irAEs. Conclusions: This cohort study found that pembrolizumab dominated the immunotherapy prescribing market, but the relative use of immunotherapy has minimally increased in patients younger than 65 years since FDA approval. irAEs were frequent and associated with key individual comorbidities. Severe irAEs were rare and associated with overall comorbidity status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
张张完成签到,获得积分10
刚刚
Lucas的应助被费可采纳,获得10
1秒前
Jasper的应助被贾文浩采纳,获得10
1秒前
帅气诗槐发布了新的文献求助10
1秒前
1秒前
阿泰完成签到,获得积分10
2秒前
真的不会完成签到,获得积分10
3秒前
Sunmq发布了新的文献求助10
3秒前
圆圆的大脑完成签到,获得积分10
3秒前
tx66发布了新的文献求助10
3秒前
jhybd完成签到 ,获得积分10
4秒前
ylw完成签到 ,获得积分10
5秒前
5秒前
瓦罐完成签到 ,获得积分10
6秒前
6秒前
6秒前
xiaole完成签到 ,获得积分10
6秒前
7秒前
01完成签到,获得积分10
7秒前
橘络完成签到,获得积分10
9秒前
帅气诗槐完成签到,获得积分10
9秒前
舒适的画板完成签到,获得积分20
9秒前
阿泰发布了新的文献求助10
9秒前
xucc发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
00完成签到,获得积分10
11秒前
楠12发布了新的文献求助10
11秒前
ig完成签到,获得积分10
11秒前
子非鱼发布了新的文献求助10
11秒前
爱听歌电灯胆完成签到 ,获得积分10
12秒前
超人子子完成签到,获得积分10
13秒前
打打的应助被敏感烤鸡采纳,获得10
13秒前
14秒前
明朗完成签到 ,获得积分10
14秒前
Da_Li完成签到,获得积分10
15秒前
茹果完成签到,获得积分10
15秒前
稳重依萱完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463